Aldeyra Therapeutics Inc stock is traded at $0.6738, with a volume of 338,517. It is up +6.33% in the last 24 hours and down -26.47% over the past month. Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma, and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.
Previous Close:
$0.6337
Open:
$0.64
24h Volume:
338,517
Relative Volume:
0.43
Market Cap:
$40.67M
Revenue:
-
Net Income/Loss:
-$27.37M
P/E Ratio:
-
EPS:
-$0.4552
Net Cash Flow:
-$25.99M
1W Performance:
+15.53%
1M Performance:
-26.47%
6M Performance:
-61.05%
1Y Performance:
-85.63%
1-Day Range:
$0.6102$0.6919
1-Week Range:
$0.5526$0.718
52-Week Range:
$0.5271$5.93
Aldeyra Therapeutics Inc Stock (ALDX) Company Profile
Name
Aldeyra Therapeutics IncSector
HealthcareIndustry
BiotechnologyPhone
781-761-4904Address
131 HARTWELL AVENUE, LEXINGTON, MA, USAMarket Cap
Revenue
Net Income
Cash Flow
EPS